Pendekatan untuk mengobati diabetes tipe 2 yang efektif pada tikus --T-REC-komunitas reptil-semarang--KSE-komunitas satwa eksotik

SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE
DISAMPING KANAN INI.............

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

.................


T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA


More info :
www.trecsemarang2011.blogspot.com
minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
08995557626
..................................
KSE – KOMUNITAS SATWA EKSOTIK – EXOTIC PETS COMMUNITY-- INDONESIA
Visit Our Community and Joint W/ Us....Welcome All Over The World
www.facebook.com/groups/komunitassatwaeksotik/
 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA
DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )
HUBUNGI   :  089617123865

.........................

Pendekatan untuk mengobati diabetes tipe 2 yang efektif pada tikus 

Kombinasi transplantasi sel induk manusia dan obat antidiabetes terbukti sangat efektif untuk meningkatkan berat badan dan metabolisme glukosa pada model tikus diabetes tipe 2 . Temuan bisa mengatur untuk uji klinis untuk menguji pendekatan berbasis sel induk yang pertama untuk penggantian insulin pada penderita diabetes tipe 2 .....read more

First stem
cell-based approach to treat type 2 diabetes effective in mice

Date:

March 19, 2015

Source:

Cell Press

Summary:

A combination of human
stem cell transplantation and antidiabetic drugs proved to be highly effective
at improving body weight and glucose metabolism in a mouse model of type 2
diabetes. The findings could set the stage for clinical trials to test the
first stem cell-based approach for insulin replacement in patients with type 2
diabetes.

..........................

A combination of human
stem cell transplantation and antidiabetic drugs proved to be highly effective
at improving body weight and glucose metabolism in a mouse model of type 2
diabetes. The findings, published March 19th by Stem
Cell Reports, could set the stage for clinical trials to test the
first stem cell-based approach for insulin replacement in patients with type 2
diabetes.

Type 2 diabetes, which accounts for 90%-95% of the now approaching 400
million cases of diabetes worldwide, is currently treated by oral medication,
insulin injections, or both to control blood glucose levels. However, insulin
delivery is imprecise, onerous, and often promotes weight gain, while drugs do
not work in some patients and may cause gastrointestinal problems or low blood
glucose levels, highlighting the strong need for better treatment options.

To address this need, senior study author Timothy Kieffer of the University
of British Columbia collaborated with BetaLogics, a division of Janssen
Research & Development, LLC, and tested a promising stem cell
transplantation approach.

First, they fed mice a high-fat diet to induce obesity, low responsiveness
to insulin, and high blood glucose levels--the hallmarks of type 2 diabetes.
The mice then received transplants of encapsulated pancreatic progenitor cells
derived from human embryonic stem cells. These transplanted cells matured into
insulin-secreting beta cells, resulting in improvements in insulin sensitivity
and glucose metabolism. Moreover, stem cell transplantation combined with
currently available antidiabetic drugs resulted in rapid weight loss in the
mice and more significant improvements in glucose metabolism compared with
either treatment alone.

Moving forward, the researchers will use their mouse model of type 2
diabetes to test the effectiveness of transplanting more mature
insulin-producing cells that could potentially reverse symptoms of diabetes
faster and at a lower dose compared to pancreatic progenitor cells.

A similar stem cell-based transplantation approach recently obtained clearance
from the US Food and Drug Administration and Health Canada to be tested in
patients with type 1 diabetes in phase1/2 clinical trials sponsored by a
regenerative medicine company called ViaCyte.

"Success in these clinical trials could pave the way for testing in
patients with type 2 diabetes," Kieffer says. "Our hope is that a
stem cell-based approach to insulin replacement will ultimately improve glucose
control in patients with both type 1 and type 2 diabetes, resulting in
healthier, longer lives."







Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited
for content and length.







Journal Reference:

1.    Jennifer E. Bruin, Nelly Saber, Natalie
Braun, Jessica K. Fox, Majid Mojibian, Ali Asadi, Campbell Drohan, Shannon
O’dwyer, Diana S. Rosman-Balzer, Victoria A. Swiss, Alireza Rezania, Timothy J.
Kieffer. Treating Diet-Induced Diabetes and Obesity with Human
Embryonic Stem Cell-Derived Pancreatic Progenitor Cells and Antidiabetic Drugs. Stem
Cell Reports, 2015 DOI:10.1016/j.stemcr.2015.02.011

http://www.sciencedaily.com/releases/2015/03/150319124004.htm

Share this: